Skip to main content
Livermore
Livermore
ZHEN

Versor Investments LP

SEC CIK
0001650301
Latest filing
Aug 7, 2026

The latest 13F from Versor Investments LP covers Q2 2026 (filed Aug 7, 2026): 27 long positions worth $47.5M. The top 10 holdings make up 55.7% of the portfolio, and the largest is Nuvalent, Inc. (NUVL) at 6.7%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$15.5M
Added
14
Est. +$8.92M
Reduced
2
Est. −$261.2K
Sold out
14
Est. −$18.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. NUVLNuvalent, Inc.
    6.7%$3.19MHistory
  2. JHGJanus Henderson Group Ltd.
    6.4%$3.04MHistory
  3. TECHBIO-TECHNE Corp
    6.3%$2.97MHistory
  4. NSCNorfolk Southern Corp
    5.6%$2.68MHistory
  5. SEMSelect Medical Holdings Corp
    5.6%$2.68MHistory

Share of portfolio

Top 5 holdings and the other 22 positions, by share of portfolio value

  1. NUVL6.7%
  2. JHG6.4%
  3. TECH6.3%
  4. NSC5.6%
  5. SEM5.6%
  6. Other 22 positions69.4%

Biggest buys

New and added positions, by estimated amount bought

  1. NUVLNuvalent, Inc.
    +$3.19MNewHistory
  2. TECHBIO-TECHNE Corp
    +$2.97MNewHistory
  3. APGEApogee Therapeutics, Inc.
    +$2.42MNewHistory
  4. CPRXCatalyst Pharmaceuticals, Inc.
    +$2.40MNewHistory
  5. UNFUnifirst Corp
    +$1.78MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NUVLNuvalent, Inc.
    +6.72 pp0.0% → 6.7%History
  2. TECHBIO-TECHNE Corp
    +6.25 pp0.0% → 6.3%History
  3. APGEApogee Therapeutics, Inc.
    +5.09 pp0.0% → 5.1%History
  4. CPRXCatalyst Pharmaceuticals, Inc.
    +5.04 pp0.0% → 5.0%History
  5. UNFUnifirst Corp
    +3.63 pp1.3% → 4.9%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. DAWNDay One Biopharmaceuticals, Inc.
    −$2.65MSold outHistory
  2. APLSApellis Pharmaceuticals, Inc.
    −$2.06MSold outHistory
  3. FOLDAmicus Therapeutics, Inc.
    −$1.97MSold outHistory
  4. GLDDGreat Lakes Dredge & Dock CORP
    −$1.73MSold outHistory
  5. THRThermon Group Holdings, Inc.
    −$1.62MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. DAWNDay One Biopharmaceuticals, Inc.
    −6.49 pp6.5% → 0.0%History
  2. APLSApellis Pharmaceuticals, Inc.
    −5.04 pp5.0% → 0.0%History
  3. FOLDAmicus Therapeutics, Inc.
    −4.82 pp4.8% → 0.0%History
  4. GLDDGreat Lakes Dredge & Dock CORP
    −4.23 pp4.2% → 0.0%History
  5. THRThermon Group Holdings, Inc.
    −3.96 pp4.0% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$47.5M
+$6.69M (+16.4%) vs. prior quarter
Positions
27
−4 vs. prior quarter
Top 10 concentration
55.7%
Top 10 as share of value
Turnover
41.2%
Q2 2026, one quarter
Average holding period
2.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.31B (Q4 2021)

Q1 2021: $1.68BQ2 2021: $2.84BQ3 2021: $3.25BQ4 2021: $3.31BQ1 2022: $2.68BQ2 2022: $2.61BQ3 2022: $1.68BQ4 2022: $1.16BQ1 2023: $762.7MQ2 2023: $577.5MQ3 2023: $494.4MQ4 2023: $491.2MQ1 2024: $494.6MQ2 2024: $542.3MQ3 2024: $631.8MQ4 2024: $580.1MQ1 2025: $613.4MQ2 2025: $567.5MQ3 2025: $543.3MQ4 2025: $641.8MQ1 2026: $40.8MQ2 2026: $47.5M
Q1 2021Q2 2026
13F filings of Versor Investments LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 7, 202627$47.5MNUVLJHGTECHvs. Q1 2026SEC
Q1 2026May 12, 202631$40.8MJHGDAWNSEMvs. Q4 2025SEC
Q4 2025Feb 4, 2026590$641.8MCMAJHGCDTXvs. Q3 2025SEC
Q3 2025Nov 6, 2025606$543.3MMRUSPBPBSCSvs. Q2 2025SEC
Q2 2025Aug 5, 2025683$567.5MBPMCFAROSKXvs. Q1 2025SEC
Q1 2025May 13, 2025681$613.4MBERYITCIDFSvs. Q4 2024SEC
Q4 2024Feb 5, 2025725$580.1MJWNCHXDFSvs. Q3 2024SEC
Q3 2024Nov 4, 2024743$631.8MDFSCHXSRCLvs. Q2 2024SEC
Q2 2024Aug 1, 2024699$542.3MDFSETRNANSSvs. Q1 2024SEC
Q1 2024May 13, 2024661$494.6MEnerplus CorpPXDSWNvs. Q4 2023SEC
Q4 2023Feb 7, 2024682$491.2MRPT RealtySOVOPXDvs. Q3 2023SEC
Q3 2023Nov 6, 2023643$494.4MACIRPT RealtySOVOvs. Q2 2023SEC
Q2 2023Aug 7, 2023594$577.5MPDCEVectivbio Hldg AGDICEvs. Q1 2023SEC
Q1 2023May 5, 2023682$762.7MAQUABKIAJRDvs. Q4 2022SEC
Q4 2022Jan 30, 2023689$1.16BCOWNBKILHCGvs. Q3 2022SEC
Q3 2022Oct 25, 2022770$1.68BLHCGUMPQBKIvs. Q2 2022SEC
Q2 2022Jul 27, 2022777$2.61BYBHVNSWCHvs. Q1 2022SEC
Q1 2022May 4, 2022603$2.68BLHCGMGPWBTvs. Q4 2021SEC
Q4 2021Feb 8, 2022528$3.31BMGPPBCTSTLvs. Q3 2021SEC
Q3 2021Nov 4, 2021497$3.25BXECPBCTPPDvs. Q2 2021SEC
Q2 2021Jul 27, 2021340$2.84BINFOXECMXIMvs. Q1 2021SEC
Q1 2021May 10, 2021236$1.68BINFOKSUFlir Sys Inc–SEC

13D and 13G filings

Companies where Versor Investments LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Versor Investments LP does not currently report owning 5% or more of any company.

Latest filings

56 filings on file made by Versor Investments LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Versor Investments LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
XENTIntersect ENT, Inc.Feb 10, 202313G/AOld format–––SEC
TSCTriState Capital Holdings, Inc.Feb 10, 202313G/AOld format–––SEC
Del Taco Restaurants, Inc.Feb 10, 202313G/AOld format–––SEC
SRRASierra Oncology, Inc.Feb 10, 202313G/AOld format–––SEC
GWBGreat Western Bancorp, Inc.Feb 10, 202313G/AOld format–––SEC
Triple-S Management CorpFeb 10, 202313G/AOld format–––SEC
GSKYGreenSky, Inc.Feb 10, 202313G/AOld format–––SEC
GNOGGolden Nugget Online Gaming, Inc.Feb 10, 202313G/AOld format–––SEC
FOEFerro CorpFeb 10, 202313G/AOld format–––SEC
CTTCatchMark Timber Trust, Inc.Feb 10, 202313G/AOld format–––SEC
CNBKACentury Bancorp IncFeb 10, 202313G/AOld format–––SEC
BMTCBryn Mawr Bank CorpFeb 10, 202313G/AOld format–––SEC
BDSIBiodelivery Sciences International IncFeb 10, 202313G/AOld format–––SEC
ATRSAntares Pharma, Inc.Feb 10, 202313G/AOld format–––SEC
ACBIAtlantic Capital Bancshares, Inc.Feb 10, 202313G/AOld format–––SEC
CTTCatchMark Timber Trust, Inc.Jun 24, 202213GOld format–New–SEC
ATRSAntares Pharma, Inc.May 6, 202213GOld format–New–SEC
SRRASierra Oncology, Inc.Apr 22, 202213GOld format–New–SEC
GNOGGolden Nugget Online Gaming, Inc.Mar 9, 202213G/AOld format–––SEC
GNOGGolden Nugget Online Gaming, Inc.Mar 3, 202213G/AOld format–––SEC